|
Negative Cooperativity in the Human Bradykinin B2
Receptor*
Anne
Pizard,
Jeannine
Marchetti,
Jacqueline
Allegrini,
François
Alhenc-Gelas, and
Rabary M.
Rajerison
From INSERM Unité 367, Physiologie et Pathologie
Expérimentale Vasculaires, 17, rue du Fer à Moulin,
75005 Paris, France
 |
ABSTRACT |
A human kidney bradykinin (BK)
B2 receptor cDNA was transfected in CHO-K1 cells
to establish cell lines that express stably and at high density a
receptor exhibiting B2 receptor properties in terms of
coupling to cell signaling effectors, desensitization, and
internalization. A cell line with a density of 1.3 × 106 receptors/cell allowed us to carry out a detailed study
of BK-receptor interaction over a wide range of BK concentrations. A
model assuming that BK binds to two receptor affinity states (depending
on guanine nucleotide-sensitive coupling) was not sufficient to account
for the kinetics of BK binding. Equilibrium kinetic analysis and
studies of the effects of receptor occupancy by agonists or antagonists on the kinetics of BK-receptor complex dissociation revealed features typical of negative cooperative binding. The negative cooperativity phenomenon was also observed in isolated membranes in both the presence
and absence of guanine nucleotide. Thus, following the interaction with
BK, B2 receptor molecules likely interact with each other,
resulting in an acceleration of bound ligand dissociation and a
decrease in the apparent affinity of the receptor for BK. This
phenomenon can participate in the desensitization process.
 |
INTRODUCTION |
Bradykinin (BK)1 is
involved in a variety of physiological and pathological processes,
including vasodilation and control of vascular tone, ion transfer in
epithelia, and pain (1). BK binds to specific receptors that have been
classified into B1 and B2 receptors according
to their relative affinities for des-Arg9-BK and BK (2).
These two types of receptors belong to the superfamily of
seven-transmembrane domain receptors (3, 4). Most of the BK effects
described so far are mediated by the B2 receptor subtype.
BK receptors are coupled through pertussis toxin-insensitive G proteins
(5, 6) to at least two separate pathways of phospholipid metabolism
(7-12), the hydrolysis of inositol phospholipids by phospholipase C
(PLC) and the release of arachidonic acid by phospholipase A2 (PLA2). PLC stimulation produces the second
messengers inositol 1,4,5-trisphosphate and diacylglycerol. Inositol
1,4,5-trisphosphate is likely responsible for the release of
Ca2+ from internal stores (13-15), and the physiological
effects of BK are thought to be strongly dependent on its ability to
mobilize [Ca2+]i. BK-induced production of
inositol phosphates, release of arachidonic acid, and elevation of
[Ca2+]i as well as the in vitro
physiological responses to BK are of a smaller magnitude in cells or
tissues preexposed to BK (7, 13, 16-19). Agonist-induced
phosphorylation of the receptor, resulting in receptor uncoupling and
modulation of receptor affinity (20, 21) and loss of cell-surface
binding sites (19, 22, 23) as a consequence of internalization of the
ligand-receptor complex (19, 23, 24), has been proposed to play a role
in the decreased responsiveness to BK. The receptor-mediated
desensitization can contribute, together with the action of kininases
and the triggering of physiological counter-regulatory mechanisms, to the limitation of the physiological action of the peptide in
vivo and reduce the potential therapeutic interest of agonists.
After the obtainment and pharmacological characterization of a
recombinant human renal BK B2 receptor that was expressed
at high density in CHO-K1 cells, we studied in detail the kinetics of
BK interaction with the receptor. This study was performed because
analysis of previous studies revealed large variations, by >4 orders
of magnitude, in the affinity constants reported for BK (4, 21, 25). Leeb-Lundberg and Mathis (26) have demonstrated that the B2 receptor can be in different affinity states depending on the presence
of guanine nucleotide. The present work demonstrates, with the analysis
of BK-receptor interaction over a wide range of ligand concentrations
and dissociation kinetic experiments, a new property of the
B2 receptor, which is negative cooperativity in the binding
of BK, a phenomenon described so far for a few seven-transmembrane
domain receptors (27-31).
 |
EXPERIMENTAL PROCEDURES |
Cloning of Human BK B2 Receptor and
Transfection--
One µg of total RNA prepared from normal human
kidney tissue (CLONTECH, Heidelberg, Germany) was
reverse-transcribed and amplified (30 cycles of 1 min at 95 °C,
1.5 min at 55 °C, and 1 min at 72 °C) using two
B2 receptor-specific primers,
5 -GGAATTCTCACTCACATCCCACTTGAGTC-3 and 5 -GGAATTCACAGCAGCCCTGCTGGC-3 ,
corresponding to the sequence of the published human fibroblast
B2 receptor (4) with an EcoRI site added at the
5 -end. The amplified fragment (1232 base pairs) was subcloned into the
EcoRI site of pBluescript KS+ (Stratagene), and
both strands were sequenced using [ -33P]dATP (Amersham
International, Buckinghamshire, United Kingdom) and an AmplicycleTM
sequencing kit (Perkin-Elmer, Langen, Germany). The cDNA differs in
position 641 by A in place of G from the published fibroblastic
sequence, but codes for the same amino acid sequence. The construct
comprising 108 base pairs upstream of the initiator methionine codon
and 30 base pairs downstream of the stop codon was digested with
XhoI and BamHI to isolate an insert that was subcloned into corresponding sites of the eucaryotic expression vector
pcDNA3 (Invitrogen, Leek, Netherlands). CHO-K1 cells
(American Type Culture Collection, Rockville, MD) were transfected with this construct using the calcium phosphate precipitation method, and
selection was done with G418 according to standard procedures (32).
Cell clones expressing the recombinant receptor were then selected on
the basis of their ability to bind [3H]BK (110 Ci/mmol;
NEN, LeBlanc Mesnil, France). These clones as well as parental CHO-K1
cells were grown in Ham's F-12 medium containing 10% fetal calf
serum, 1 mM glutamine, 0.2 units/ml penicillin, 20 pg/ml
streptomycin, and 0.5 mg/ml amphotericin B and maintained at 37 °C
in a humidified water-jacketed incubator with 5% CO2. BK
receptor expression was stable for at least 30 passages.
Measurement of [3H]BK Binding in Intact
Cells--
Binding assays were carried out on confluent cells grown on
24- or 48-well plates (~500,000 or 250,000 cells/well, respectively). After two washes with 0.5 ml of HBSS (0.33 mM
Na2HPO4, 0.44 mM KH2PO4, 127 mM NaCl, 5 mM KCl, 20 mM NaHCO3, 5 mM glucose, 10 mM sodium acetate, 0.8 mM MgSO4, and 1.5 mM
CaCl2, pH 7.4), [3H]BK binding was performed
for various times at 37 or 4 °C in 0.3 ml of HBSS containing 0.1%
BSA and protease inhibitors (8 × 10 2 units/ml
aprotinin, 0.1 mg/ml bacitracin, 1 mM 1,10-phenanthroline, and 10 5 M captopril). Equilibrium studies
were performed with incubation times of 1 and 16 h at 37 and
4 °C, respectively. Nonspecific binding was determined in the
presence of a 1000-fold excess of unlabeled BK and substracted from
total binding. It did not exceed 10% of total binding. The
dissociation of the [3H]BK-receptor complex was followed
at 4 °C in the absence or presence of unlabeled BK in cells labeled
with variable amounts of [3H]BK and washed with HBSS
containing 0.1% BSA.
The following BK analogues were tested in the range of
10 10 to 10 5 M for their ability
to compete for 1 nM [3H]BK binding at
37 °C: [Hyp3,Tyr(Me)8]BK,
[Aib7]BK, HOE 140, Lys-des-Arg9-BK,
des-Arg9-BK, des-Arg9-[Leu8]BK,
and
D-Arg-[Hyp3,D-Phe7,Leu8]BK
(33). The effects of these compounds on the dissociation rate of the
[3H]BK-receptor complex at 4 °C were also studied in
cells prelabeled with 2 nM [3H]BK.
The bound radiolabeled ligand was separated from the free ligand by
three successive washes with 0.5 ml of ice-cold HBSS. Cell-bound
radioactivity was determined by scintigraphy (LKB 1211 Rackbeta,
Wallac) either after cell lysis with 0.2 ml of 1 N NaOH or
after acid washing according to Haigler et al. (34). This technique consisted of a 4-min treatment with 0.5 ml of ice-cold acid
buffer (0.2 N acetic acid and 0.5 N NaOH, pH
2.5) followed by cell lysis with 1 N NaOH to dissociate the
radioactivity bound to the cell surface, which is removed by acid
washing, from internalized radioactivity, which is acid-resistant.
Control experiments established that the sum of acid-sensitive binding
plus acid-resistant binding gave values similar to those determined
after simple cell lysis with NaOH.
In some experiments, cells were pretreated with unlabeled BK to induce
desensitization before the determination of cell-surface [3H]BK binding. In these experiments, free BK and cell
surface-bound unlabeled BK were removed by washing with 0.5 ml of
ice-cold HBSS and a 4-min treatment with 0.5 ml of ice-cold acid buffer
(90 mM NaCl, 50 mM sodium citrate, and 0.2 mM Na2HPO4, pH 5) plus two washes
with 0.5 ml of ice-cold HBSS, and [3H]BK binding was then
performed for 16 h at 4 °C. In each culture plate, the protein
content was determined according to the manufacturer's instructions
(Bio-Rad, München, Germany) in three wells using BSA as a
standard to normalize the results per mg of cell protein. The specific
binding determined after a 1-h incubation at 37 °C with
10 7 M [3H]BK was 8.34 ± 2.50 pmol of [3H]BK bound per mg of protein (mean ± S.D., n = 18).
Measurement of [3H]BK Binding in Isolated Cell
Membranes--
After rinsing with phosphate-buffered saline, cells
grown on 75-cm2 flasks were scraped and homogenized in 5 mM Tris-HCl, 225 mM sucrose, 5 mM
EDTA, and 2 mM MgCl2, pH 7.4, with a
Potter-Elvehjem homogenizer in an ice bath. Protease inhibitors
(leupeptin (10 µM), pepstatin (0.7 µg/ml), aprotinin
(80 units/ml), and Pefabloc (0.5 mM)) were added. Cell
debris were eliminated by centrifugation at 100 × g
for 15 min at 4 °C, and a particulate fraction was pelleted at
1500 × g for 15 min in a Sorvall SS34 rotor. The
pellet (referred to as cell membranes) was resuspended in the same
medium without sucrose and frozen at 80 °C until use.
[3H]BK binding was performed in a medium containing 50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, pH 7.4, and protease inhibitors. Bound
radioactivity was separated from free ligand by filtration using
Millipore HVLP02500 filters.
Measurement of Phospholipase C Activity--
Cells grown on
24-well plates were labeled with 4 µCi/ml
[3H]myoinositol (10-20 Ci/mmol; Amersham International)
for 20 h in Ham's F-12 medium. Extracellular unincorporated
radioactivity was then removed by three washes with 0.5 ml of HBSS
containing 0.1% BSA. Incubation with test compounds or vehicles was
carried out at 37 °C in 0.3 ml of the above solution in the presence
of protease inhibitors and 10 mM LiCl. For desensitization
experiments, cells were preincubated with BK, phorbol 12-myristate
13-acetate, or staurosporine in the absence of lithium. After stopping
the reaction with 200 µl of 7.5% ice-cold perchloric acid, cells
were scraped and transferred into glass tubes. The separation of the different cellular pools labeled with [3H]myoinositol was
performed as described previously in detail (35) using AG 1-X8 anion
exchange column chromatography (formate form, 100-200 mesh; Bio-Rad).
Results are expressed as the ratio between the radioactivity determined
in the inositol phosphate (IP)-containing pool and the radioactivity in
all inositol-containing pools.
Measurement of Phospholipase A2
Activity--
Confluent cultures in 24-well plates were labeled to
equilibrium with 1 µCi/ml [3H]arachidonic acid
(150-230 Ci/mmol; Amersham International) for 20 h. To eliminate
unincorporated radioactivity, cells were then rinsed at 37 °C: three
times with 1 ml of phosphate-buffered saline, once with 1 ml of HBSS,
and twice for 20 min with 1 ml of HBSS containing 0.1% fatty acid-free
BSA. Phospholipase A2 activation experiments were then
performed in 0.5 ml of HBSS containing 0.1% BSA and protease
inhibitors at 37 °C for 10 min and started by adding test compounds
or vehicles and stopped by the removal of the incubation medium. The
incubation medium was then centrifuged (1000 × g for 5 min), and
0.35 ml of supernatant containing the released
[3H]arachidonic acid were transferred into counting vials
for liquid scintigraphy. Cell-associated radioactivity was also
determined after lysis with 0.2 ml of 1 N NaOH to express
results as the ratio between the medium radioactivity containing the
[3H]arachidonic acid released and the sum of the medium
plus cell-associated radioactivity. The radioactivity in the medium
corresponds to the sum of [3H]arachidonic acid plus
derived 3H-labeled metabolites.
Measurement of Variations in Intracellular Calcium
Concentration--
Cells were subcultured on a thin glass microscope
coverslip coated with polyornithine (150 µg/ml). Then, they were
loaded with 5 µM fura-2/AM plus 0.01% pluronic acid at
room temperature for 2 h. The glass coverslip carrying the cells
was glued to the bottom of the superfusion chamber and fixed to the
stage of an inverted fluorescent microscope equipped with a 40-fold
magnification fluorescence objective (Nikon). Cells were continuously
superfused, and fluorescence was measured with a PTI Photoscan II
microfluorometer as described previously (36).
Statistical Analysis--
Results are presented as means ± S.D. in the text, tables, and figure legends and are plotted as
means ± S.E. on the figures. Comparisons between experimental
conditions were performed by analysis of variance.
 |
RESULTS |
This study was performed on stable CHO-K1 cell lines transfected
with BK B2 receptor cDNA synthesized from human kidney
RNAs. No [3H]BK binding and no BK activation of PLC and
PLA2 were detected in nontransfected CHO-K1 cells. One
clone (hB2r-CHO) with a high density of
[3H]BK-binding sites (1.3 × 106
sites/cell) was used for the experiments. The recombinant receptor in
this clone exhibited biochemical and pharmacological features typical
of a bradykinin B2 receptor subtype. BK application induced PLC and PLA2 activation with EC50 values of
0.22 ± 0.06 (n = 3) and 1.10 ± 0.20 (n = 3) nM and maximal stimulation of 33- and 6-fold the basal value, respectively. BK application elevated the
cytosolic calcium concentration. Also, as reported for other B2 receptor-expressing cells (7, 13, 19, 20, 22, 23), PLC,
PLA2, and calcium responses were desensitized following BK application. This was associated with internalization of cell-surface binding sites, a highly temperature-sensitive process that occurred as
complexes with BK as evidenced by an acid-salt washing technique. Using
2 × 10 8 M [3H]BK, the
internalization represented 62.0 ± 10.7% of the total binding
determined after a 1-h incubation at 37 °C (n = 5)
and only 4.4 ± 2.7% (n = 5) when the binding
assay was performed for 16 h at 4 °C. The EC50
values (BK concentration during preincubation) for the desensitization
of PLC and PLA2 responses to 10 7
M BK were roughly of 0.1 and 2 nM,
respectively. Finally, [3H]BK binding was specifically
inhibited by B2 receptor agonists and antagonists, and PLC
was selectively activated by B2 receptor agonists (Table
I). A peculiarity of hB2r-CHO
cells that might be related to receptor overexpression is that none of
the BK-induced phenomena ([3H]BK binding, receptor
internalization rate, and activation of PLC or PLA2) were
sensitive to phorbol 12-myristate 13-acetate and staurosporine, an
activator and an inhibitor of protein kinase C, respectively (data not
shown). It is conceivable that the protein kinase C content in CHO
cells is low compared with the receptor content and that only a small
undetectable portion of the receptors could be altered by protein
kinase C.
View this table:
[in this window]
[in a new window]
|
Table I
Effects of various structural analogues of BK on [3H]BK
binding and IP production in hB2r-CHO cells
Cells were incubated with [3H]BK (1 nM) in the
absence or presence of the indicated concentrations of unlabeled BK or
analogue for 1 h at 37° C and with the analogue alone or with
both 1 nM BK and analogue before determinations of
[3H]BK binding and of IP production, respectively. Values are
from six determinations.
|
|
Fig. 1 illustrates a comparison of the
equilibrium binding of a very wide range of [3H]BK
concentrations (from 3 × 10 10 to 10 7
M) at 37 and 4 °C. Fig. 1a shows that 4 and
37 °C binding curves were not superimposable. The binding was
greater at 4 °C than at 37 °C at low [3H]BK
concentrations, and the opposite was observed when the
[3H]BK concentration exceeded 5 × 10 8
M. At both temperatures, maximal binding was not achieved
at the highest [3H]BK concentration tested. The data gave
curvilinear plots (Fig. 1b) when tested according to
Scatchard (37), whereas Hill plots (Fig. 1b,
inset) gave straight lines (r = 0.99) that
differed (p < 0.05) in their slope and gave Hill
coefficient values below 1: 0.54 ± 0.09 and 0.71 ± 0.05 for
binding at 4 and 37 °C, respectively. These observations indicate
that at both temperatures, [3H]BK binds to a
heterogeneous population of binding sites with differing affinities or
in a negative cooperative manner, which implies that receptor affinity
decreases with increased receptor occupancy (38). They also indicate
that the internalization of the [3H]BK-receptor complexes
that occurs at 37 °C is accompanied by a recycling of the receptor
back to the cell surface, which explains why maximal binding is greater
at 37 °C than at 4 °C. The fact that, at low [3H]BK
concentrations, the binding was less at 37 °C than at 4 °C will
be discussed later.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 1.
Dose dependence of [3H]BK
binding at 4 and 37 °C. The graphs represent the data of
[3H]BK binding experiments at 4 and 37 °C with intact
cells. In each experiment, specific binding (B) is expressed
as a percentage of the specific binding determined at 37 °C with
10 7 M [3H]BK. F is
the concentration (in M) of free [3H]BK
calculated from the unbound radioactivity. a, the
B value is represented as a function of the F
value. b, the same data are represented using either the
Scatchard coordinates to estimate the maximal binding capacity
(Bmax) using binding values at the three highest
[3H]BK concentrations or the Hill coordinates
(inset) to estimate the free [3H]BK
concentration (K) corresponding to half-saturation of
binding sites and the Hill coefficient (nH) of
binding. Bmax was equal to 124 ± 9 and
199 ± 14% of the specific binding (2.04 ± 0.23 pmol of
[3H]BK/mg of protein) determined at 37 °C with
10 7 M [3H]BK; K was
12 ± 2 and 62 ± 3 nM; and
nH was 0.54 ± 0.09 (r = 0.98) and 0.71 ± 0.05 (r = 0.99) at 4 and
37 °C, respectively. Values are from three independent experiments,
each performed in duplicate.
|
|
All experiments described below were aimed at testing the hypothesis of
negative cooperativity among the B2 receptors. This was
done by studying in intact cells or cell membranes the dissociation of
the BK-receptor complexes especially with regard to whether or not it
depends on the receptor occupancy level. When intact cells were used,
experiments were performed at 4 °C to avoid ligand-receptor internalization and enzymatic alterations of the receptor. Fig. 2a shows that the dissociation
of [3H]BK-receptor complexes had at least two components
with differing rates. The presence of unlabeled BK during the
dissociation reaction accelerated the complex dissociation. Thus, the
rate of the slowest dissociation component, which was 2.2 ± 0.5 10 4 min 1 in the absence of unlabeled BK,
increased to 6.6 ± 1.9 and 11.5 ± 1.9 10 4
min 1 when 2 and 100 nM unlabeled BK,
respectively, were present in the solution, indicating that the
unlabeled BK accelerating effect occurs in a dose-dependent
manner. The dose dependence of this effect was studied in more detail
in cells previously labeled with 2 nM [3H]BK
(Fig. 2b). The acceleration of [3H]BK
dissociation was detected with 4 × 10 10
M BK (p < 0.05) in these cells and was
maximal at ~1 µM unlabeled BK. These observations
clearly demonstrate that occupancy of free binding sites by unlabeled
BK results in an accelerated dissociation of already bound
[3H]BK. Furthermore, the greater the number of binding
sites occupied by unlabeled BK, the faster the dissociation of the
complex.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
Accelerated dissociation of bound
[3H]BK by unlabeled BK. All experimental steps were
carried out at 4 °C. They included a 20-h incubation of cells with 2 nM [3H]BK, extensive washing with HBSS
containing 0.1% BSA to remove unbound [3H]BK, and a
second incubation in the absence or presence of unlabeled BK with
determination of the specific binding fractions that were released in
the medium or remained associated with cells. The cell-associated
binding is expressed as a percentage of the specific binding determined
just before the dissociation reaction. a, the second
incubation was performed for the different indicated times without
(no addition) or with unlabeled BK (2 or 100 nM). The slope of the regression lines corresponding to
cell-associated binding values at 60, 180, and 300 min was determined
to estimate the dissociation rate constant given under "Results."
b, the second incubation was performed for 3 h with the
indicated unlabeled BK concentrations. Values are from three
independent experiments, each performed in duplicate.
|
|
The dependence of BK-receptor dissociation on receptor occupancy was
also demonstrated by the experiments depicted in Fig. 3, which shows that, in the absence of
unlabeled BK, the dissociation of bound [3H]BK was faster
when there was an initial occupancy of a greater number of binding
sites. The dissociation rates of the slow component were 0.8 ± 0.2 and 3.7 ± 1.2 10 4 min 1 with
initial occupancies of 0.050 ± 0.005 and 0.951 ± 0.130 pmol of [3H]BK/mg of protein, respectively.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
Dependence of [3H]BK
dissociation rate on receptor occupancy level. Experiments were
conducted and data were expressed as explained in the legend to Fig.
2a, except that cells were labeled with 10 10
or 10 8 M [3H]BK, and no
unlabeled BK was added during the dissociation reaction. The specific
binding before dissociation was 0.050 ± 0.005 and 0.951 ± 0.130 pmol of [3H]BK/mg of protein, respectively. The
dissociation rate constants given under "Results" were estimated
from cell-associated binding values at 120, 180, 300, and 480 min.
Values are from three independent experiments, each performed in
triplicate.
|
|
Table II summarizes the effects of
various structural BK analogues on [3H]BK dissociation
studied at 4 °C using the same experimental conditions used as for
BK. The effects of these analogues on [3H]BK binding and
PLC activity at 37 °C are presented in Table I to indicate their
agonist or antagonist properties in hB2r-CHO cells. The
data show that, like BK, the two B2 receptor agonists [Hyp3,Tyr(Me)8]BK and [Aib7]BK
accelerated the dissociation of bound [3H]BK;
[Aib7]BK, a strong agonist that is able to induce an
increase in IP production 1.7-fold higher than the maximal response to
BK, produced the same effect as BK on [3H]BK
dissociation.
D-Arg-[Hyp3,D-Phe7,Leu8]BK,
which behaved as a partial agonist, and the B2 receptor
antagonist HOE 140, which completely inhibited BK-sensitive IP
production, were also able to accelerate [3H]BK
dissociation. Similar results were obtained with
[D-Phe7]BK, which is another B2
receptor antagonist (33). In contrast, the B1 receptor
agonists (Lys-des-Arg9-BK and des-Arg9-BK) and
antagonist (des-Arg9-[Leu8]BK), which had no
effect on [3H]BK binding and PLC activity, did not alter
the dissociation of bound [3H]BK. These observations
demonstrate that the acceleration of [3H]BK dissociation
is a common feature of all BK analogues that are able to interact with
the B2 receptor, whether they are agonists or
antagonists.
View this table:
[in this window]
[in a new window]
|
Table II
Effects of the addition of various structural BK analogues on the
dissociation of bound [3H]BK
Experiments and expression of data were as explained in the legend to
Fig. 2b except that the 3-h dissociation reaction was performed with the indicated concentrations of analogues. Dissociations without and with 10 7 M unlabeled BK were included
as controls. Values are from eight determinations.
|
|
Experiments were performed on isolated cell membranes to test in this
system the effect of BK on the dissociation kinetics and the role of
guanine nucleotide. When such experiments were performed at 4 °C,
[3H]BK dissociation was very slow and was not sensitive
to unlabeled BK (10 7 M), GTP S
(10 5 M), or a combination of both. After a
5-h incubation, it represented in all cases only ~10% of the
[3H]BK specifically bound to cell membranes labeled with
2 nM [3H]BK (data not shown). However, at
25 °C, [3H]BK dissociation was increased by GTP S as
illustrated in Fig. 4. Unlabeled BK was
also able to accelerate dissociation at this temperature. More
important, the BK effect was observed both in the absence and presence
of the guanine nucleotide. These results clearly demonstrate that
guanine nucleotide is not necessary for the acceleration of BK
dissociation that follows an increase in the receptor occupancy
level.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 4.
Accelerated dissociation of bound
[3H]BK by unlabeled BK in isolated hB2r-CHO
cell membranes: effect of guanine nucleotide. Experiments were
carried out at 25 °C. Cell membranes were incubated for 90 min with
2 nM [3H]BK. Then, 50-µl aliquots of the
reaction mixture were transferred into 5 ml of
[3H]BK-free incubation medium with no addition or with
unlabeled BK (100 nM), GTP S (10 µM), or
both. 3H radioactivity bound to membranes was determined at
the times indicated. After substraction of nonspecific binding measured with cell membranes incubated with 2 nM
[3H]BK plus 2 µM unlabeled BK, values were
expressed as a percentage of the specific binding determined just
before the dissociation reaction. Values are from six
determinations.
|
|
 |
DISCUSSION |
This study provides, for the first time, evidence that the
interaction between BK and the BK B2 receptor exhibits
negative cooperativity. This phenomenon implies that BK binding is
accompanied by a decrease in receptor affinity.
The cells used in this study were CHO-K1 cells transfected with a BK
B2 receptor cDNA synthesized from human kidney RNAs. A
cell clone (hB2r-CHO) that expresses the receptor stably
and at high density (1.3 × 106 sites/cells) was used
for this study because it allowed us to analyze the ligand-receptor
interaction over a wide range of ligand concentrations.
Our data show that the specific [3H]BK binding to
hB2r-CHO cells displays heterogeneous features in terms of
binding affinity (curvilinear Scatchard plots and a Hill coefficient
value less than unity) and [3H]BK dissociation rate (more
than one component). Such a heterogeneity cannot be accounted for by
the presence of other BK receptors in addition to the recombinant
receptor. Indeed, there was no specific [3H]BK binding,
no BK activation of PLC and PLA2, and no increase in
cytosolic calcium upon the application of BK in the parental nontransfected CHO-K1 cells (data not shown). Also, we can exclude that
the heterogeneity in the [3H]BK binding is related to the
receptor internalization/recycling process, which was almost abolished
at the temperature of 4 °C chosen for the experiments. This was
further supported by the observation that [3H]BK binding
resulted also in curvilinear Scatchard plots (data not shown) in the
presence of sucrose, which inhibits endocytosis by disrupting
clathrin-coated vesicles (39). The use of sucrose to abolish
internalization was, however, not considered appropriate in the present
work because besides the suppression of internalization, sucrose also
markedly reduced the capacity of hB2r-CHO cells to bind BK
(data not shown), as has also been reported for the binding of growth
hormone to its receptor in IM-9 cells (40). Moreover, lowering the
temperature to 4 °C has the advantage of preventing agonist-induced
functional coupling of the receptor to cell signaling effectors and
abolishing cellular enzymatic events like phosphorylation that can
modify receptor structure and binding affinity (20, 21). In addition,
its combination with the use of protease inhibitors prevented ligand or
receptor degradation, a condition required to study the kinetics of
ligand binding.
The data obtained in the equilibrium binding studies support a negative
cooperativity phenomenon in BK binding. However, the curvilinear
Scatchard plots and the observation of a faster [3H]BK
dissociation rate from cells prelabeled with high compared with low
[3H]BK concentrations could also be interpreted by the
finding of Leeb-Lundberg and Mathis (26) that the unoccupied
B2 receptor can exist in various states that have different
affinities for BK. By using cell membranes from bovine myometrium and
incubating these membranes in the absence of guanine nucleotide, a
situation that is comparable to that prevailing in our intact cells
incubated at 4 °C (no functional receptor coupling to cell signaling
effectors), these authors demonstrated that BK binds to at least two
states of the B2 receptor, which consist of a guanine
nucleotide-insensitive low affinity state (occupied at high BK
concentrations only) from which BK dissociates quickly and a guanine
nucleotide-sensitive high affinity state from which BK dissociates
slowly. The existence of a guanine nucleotide-sensitive high affinity
state of the hB2r-CHO cell B2 receptor is
suggested by the fact that at low [3H]BK concentrations,
equilibrium binding was less at 37 °C than at 4 °C despite the
[3H]BK accumulation through the receptor
internalization/recycling process that occurred at 37 °C, but not at
4 °C. This decrease in [3H]BK binding at 37 °C is
probably related to a cellular GTP effect and involves a guanine
nucleotide-sensitive process that is responsible for receptor and G
protein coupling to cell signaling effectors and for decreases in
receptor affinity like the guanine nucleotide-induced reduction in
receptor affinity described by Leeb-Lundberg and Mathis (26) in
myometrial cell membranes. In addition, as in myometrial cell membranes
(26), [3H]BK dissociation was increased by guanine
nucleotide in cell membranes prepared from hB2r-CHO.
However, it should be pointed out that a model in which BK interacts in
a bimolecular independent fashion with two receptor states cannot
entirely account for the equilibrium kinetics observed and for the time
courses of BK dissociation observed in hB2r-CHO cells.
Indeed, when compared with a theoretical Scatchard plot for such a
model (Fig. 5), the data points occupy a
rightward position in the graph, suggesting that the affinity of the
high affinity state declines with increasing binding site occupancy and
that of the low affinity state increases with decreasing binding site
occupancy. Moreover, the slow dissociation component, reflecting
[3H]BK dissociation from the high affinity receptor
state, was more rapid in cells labeled with the higher concentration of
[3H]BK, indicating that the affinity of this state
decreased when the density of [3H]BK-receptor complexes
was increased (Fig. 3). A similar observation is apparent in the study
of Leeb-Lundberg and Mathis (26) with myometrial cell membranes.
Therefore, these experiments suggest that a phenomenon of negative
cooperativity can modulate B2 receptor affinity, whether
the receptor is in its guanine nucleotide-insensitive or -sensitive
state. According to published studies, the dissociation constant for BK
binding to the B2 receptor (Kd) may fall between 0.003 and 50 nM, and the B2 receptor
may exist in one (19, 41), two (4, 17), or three affinity states (21, 26). We believe that these discrepancies result at least partly from
the use of a low (4, 11, 17, 21), intermediate (21, 41, 42), or high
(7, 17, 19, 21) labeled BK concentration and from a narrow (4, 11, 19,
41, 42) or wide (17, 21, 26) concentration range of labeled BK, which
can prevent observation of the binding regulation by G protein and the
cooperativity phenomenon. In the present study, BK binding was studied
over 3 orders of magnitude of BK concentrations. This was possible because of the high density of the B2 receptor in
hB2r-CHO cells.

View larger version (8K):
[in this window]
[in a new window]
|
Fig. 5.
Binding with two independent categories of
binding sites does not account for [3H]BK binding in
hB2r-CHO cells. Points in the graph correspond to
[3H]BK binding experiments at 4 °C as described in the
legend to Fig. 1. The curve corresponds to a theoretical binding with
two independent binding sites. The capacity and affinity of these sites
were chosen so as to obtain the best fit of the curve with the three
extreme left and three extreme right experimental points. Bmax values (expressed as a percentage of the
binding at 37 °C with 10 7 M
[3H]BK, as described in the legend to Fig. 1) were 25 and
99%, and Kd values were 0.27 and 72 nM
for these high and low affinity sites, respectively.
|
|
The experiments that we believe demonstrate unambiguously negative
cooperativity in BK binding are those following the effect of unlabeled
BK and of B2 antagonists on the dissociation rate of the
[3H]BK-receptor complex, an effect that cannot be
accounted for by inhibition of reassociation of dissociated
[3H]BK under the experimental conditions used. In cells
prelabeled with a fixed concentration of [3H]BK, washed
to remove the unbound radioligand, and then challenged with various
concentrations of unlabeled peptide, the added BK clearly accelerated
the dissociation of the already bound [3H]BK. This
indicates that an increase in the density of ligand-receptor complexes
by unlabeled BK binding to free receptor molecules induces a decrease
in receptor affinity. The rate of [3H]BK dissociation
from the high affinity state (slow dissociation component) increased in
parallel with the degree of free receptor occupancy by added unlabeled
BK. In cells previously labeled with 2 nM
[3H]BK, a significant acceleration of
[3H]BK dissociation was observed with only 4 × 10 10 M unlabeled BK, indicating that a very
slight increase in receptor occupancy is sufficient to alter receptor
affinity. It is of interest that when experiments were performed with
cell membrane preparations, no acceleration of [3H]BK
dissociation could be obtained at 4 °C even with 10 7
M unlabeled BK. However, an accelerated dissociation was
observed if the temperature was increased to 25 °C, suggesting that
cell membrane fluidity, very likely reduced following the cell membrane preparation, can play an important role in the phenomenon of negative cooperativity (29). The fact that accelerated dissociation could be
observed with isolated cell membranes in the absence as well presence
of guanine nucleotide further demonstrates that the phenomenon of
negative cooperativity can modulate B2 receptor affinity
whether or not the receptor is coupled to G protein, as already
stated.
Finally, B2 receptor antagonists like BK and other
B2 receptor agonists were also able to accelerate the
dissociation of bound [3H]BK. Since B2
receptor antagonists fail to elicit any cell response and stabilize a G
protein-uncoupled form of the receptor (43), this observation implies
that the phenomenon of negative cooperativity can occur independently
of functional receptor and G protein coupling to signaling effectors.
Negative cooperativity in binding to other G protein-coupled receptors,
adrenergic receptors, has also been documented by the use of
antagonists (29, 31). Thus, in some receptors, including the BK
B2 receptor, antagonists apparently possess two
complementary actions, which are to prevent the binding of agonist to
free receptor and to facilitate the dissociation of bound agonist.
In conclusion, the high expression of a renal human B2
receptor in CHO cells enabled us to characterize a negative
cooperativity among B2 receptors. Following their
interaction with BK molecules, B2 receptor molecules very
likely interact with each other, leading to an acceleration of bound BK
dissociation. Such a receptor-receptor interaction has been proposed
for the thyrotropin receptor expressed in CHO cells, for which a
progressive reduction in affinity for thyrotropin was observed with
increasing numbers of receptors (27). This indicates that increasing
the probability for the interaction between receptor molecules favors
the phenomenon of negative cooperativity in binding. This has been
proposed for receptors that are expressed endogenously to much less
extent but that can form clusters or aggregate after ligand binding
(44). Interaction between receptor molecules has also been suggested for other receptors. Thus, angiotensin II binding was restored following the coexpression of two single-point mutants of the angiotensin II A1 receptor that were each deficient in
ligand binding capacity (45). Similarly, a restoration of
carbachol-induced PI hydrolysis has been reported following the
coexpression of two fragmented muscarinic m3 receptors
deficient in their ability to bind the agonist and to stimulate IP
production (46, 47). A protein-protein interaction within the plasma
membrane may therefore cause a loss or a gain of functional properties.
The present study is the first description of the involvement of
negative cooperativity in the desensitization process of the human
bradykinin B2 receptor. The molecular basis of this
phenomenon is not yet understood for the B2 receptor.
 |
ACKNOWLEDGEMENTS |
We thank Pr. D. Regoli for the gift of
unlabeled bradykinin B2 analogues and Nathalie Coustou for
secretarial assistance.
 |
FOOTNOTES |
*
This work was supported by INSERM and by a grant from the
Bristol-Meyers Squibb Institute for Medical Research (Princeton, NJ).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
33-1-45-87-61-00; Fax: 33-1-45-35-66-29; E-mail:
aprsu367{at}pratique.fr.
1
The abbreviations used are: BK, bradykinin; PLC,
phospholipase C; PLA2, phospholipase A2; CHO,
Chinese hamster ovary; HBSS, Hanks' balanced saline solution; BSA,
bovine serum albumin; Aib, 2-aminoisobutyric acid; IP, inositol
phosphate; GTP S, guanosine 5 -O-(3-thiotriphosphate).
 |
REFERENCES |
-
Bhoola, K. D.,
Figueroa, C. D.,
and Worthy, K.
(1992)
Pharmacol. Rev.
44,
1-80[Medline]
[Order article via Infotrieve]
-
Regoli, D.,
and Barabé, J.
(1980)
Pharmacol. Rev.
32,
1-46[Medline]
[Order article via Infotrieve]
-
Menke, J. G.,
Borkowski, J. A.,
Bierilo, K. K.,
MacNeil, T.,
Derrick, A. W.,
Schneck, K. A.,
Ransom, R. W.,
Strader, C. D.,
Linemeyer, D. L.,
Hess, J. F.
(1994)
J. Biol. Chem.
269,
21583-21586[Abstract/Free Full Text]
-
Hess, J. F.,
Borkowski, J. A.,
Young, G. S.,
Strader, C. D.,
Ransom, R. W.
(1992)
Biochem. Biophys. Res. Commun.
184,
260-268[CrossRef][Medline]
[Order article via Infotrieve]
-
Liao, J. K.,
and Homcy, C. J.
(1993)
J. Clin. Invest.
92,
2168-2172
-
Voyna-Yasenetskaya, T.,
Tkachuk, V.,
Cheknyova, E.,
Pachenko, M.,
Grigorian, G.,
Vareck, R.,
Stewart, J.,
and Ryan, U.
(1989)
FASEB J.
3,
44-51[Abstract]
-
Roscher, A. A.,
Manganiello, V. C.,
Jelsema, C. L.,
Moss, J.
(1984)
J. Clin. Invest.
74,
552-558
-
Wiernas, T. K.,
Griffin, B. W.,
and Sharif, N. A.
(1997)
Br. J. Pharmacol.
121,
649-656[CrossRef][Medline]
[Order article via Infotrieve]
-
Tropea, M. M.,
Gummelt, D.,
Herzig, M. S.,
Leeb-Lundberg, L. M. F.
(1993)
J. Pharmacol. Exp. Ther.
264,
930-937[Abstract/Free Full Text]
-
Liebmann, C.,
Graness, A.,
Ludwig, B.,
Adomeit, A.,
Boehmer, A.,
and Boehmer, F.-D.
(1996)
Biochem. J.
313,
109-118
-
Hess, J. F.,
Borkowski, J. A.,
MacNeil, T.,
Stonesifer, G. Y.,
Fraher, J.,
Strader, C. D.,
Ransom, R. W.
(1993)
Mol. Pharmacol.
45,
1-8[Abstract]
-
Eggerickx, D.,
Raspe, E.,
Bertrand, D.,
Vassart, G.,
and Parmentier, M.
(1992)
Biochem. Biophys. Res. Commun.
187,
1306-1313[CrossRef][Medline]
[Order article via Infotrieve]
-
Quitterer, U.,
Schröder, C.,
Müller-Esterl, W.,
and Rehm, H.
(1995)
J. Biol. Chem.
270,
1992-1999[Abstract/Free Full Text]
-
Ardaillou, N.,
Blaise, V.,
Costenbader, K.,
Vassitch, Y.,
and Ardaillou, R.
(1996)
Am. J. Physiol.
271,
F754-F761[Abstract/Free Full Text]
-
Mathis, S. A.,
Criscimagna, N. L.,
and Leeb-Lundberg, L. M. F.
(1996)
Mol. Pharmacol.
50,
128-139[Abstract]
-
Coggan, J. S.,
and Thompson, S. H.
(1995)
Am. J. Physiol.
269,
C841-C848[Abstract/Free Full Text]
-
Praddaude, F.,
Tack, I.,
Emond, C.,
Bascands, J.-L.,
Girolami, J.-P.,
Tran-Van, T.,
Regoli, D.,
and Ader, J.-L.
(1995)
Eur. J. Pharmacol.
94,
173-182
-
Smith, J. A. M.,
Webb, C.,
Holford, J.,
and Burgess, G. M.
(1995)
Mol. Pharmacol.
47,
525-534[Abstract]
-
Weintraub, W. H.,
Negulescu, P. A.,
Machen, T. E.
(1992)
Am. J. Physiol.
263,
C1029-C1039[Abstract/Free Full Text]
-
Blaukat, A.,
Abd Alla, S.,
Lohse, M. J.,
Müller-Esterl, W.
(1996)
J. Biol. Chem.
271,
32366-32374[Abstract/Free Full Text]
-
Roberts, R. A.,
and Gullick, W. J.
(1990)
Biochemistry
29,
1975-1979[CrossRef][Medline]
[Order article via Infotrieve]
-
Wolsing, D. H.,
and Rosenbaum, J. S.
(1991)
J. Pharmacol. Exp. Ther.
257,
621-633[Abstract/Free Full Text]
-
Munoz, C. M.,
and Leeb-Lundberg, L. M. F.
(1992)
J. Biol. Chem.
267,
303-309[Abstract/Free Full Text]
-
Munoz, C. M.,
Cotecchia, S.,
and Leeb-Lundberg, L. M. F.
(1993)
Arch. Biochem. Biophys.
301,
336-344[CrossRef][Medline]
[Order article via Infotrieve]
-
Roberts, R. A.,
and Güllick, W. J.
(1989)
J. Cell Sci.
94,
524-535
-
Leeb-Lundberg, L. M. F.,
and Mathis, S. A.
(1990)
J. Biol. Chem.
265,
9621-9627[Abstract/Free Full Text]
-
Chazenbalk, G. D.,
Kakinuma, A.,
Jaume, J. C.,
McLachlan, S. M.,
Rapaport, B.
(1996)
Endocrinology
137,
4586-4591[Abstract]
-
Casado, V.,
Mallol, J.,
Canela, E. I.,
Lluis, C.,
Franco, R.
(1991)
FEBS Lett.
286,
221-224[CrossRef][Medline]
[Order article via Infotrieve]
-
Limbird, L. E.,
and Lefkowitz, R. J.
(1976)
J. Biol. Chem.
251,
5007-5014[Abstract/Free Full Text]
-
Marasco, W. A.,
Feltner, D. E.,
and Ward, P. A.
(1985)
J. Cell. Biochem.
27,
359-375[CrossRef][Medline]
[Order article via Infotrieve]
-
Periyasamy, S. M.,
and Somani, P.
(1985)
Eur. J. Pharmacol.
116,
17-24[CrossRef][Medline]
[Order article via Infotrieve]
-
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manuel, 2nd Ed., pp. 1632-1633, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
-
Hall, M. J.
(1993)
Pharmacol. Ther.
56,
131-190
-
Haigler, H. T.,
Maxfield, F. R.,
Willingham, M. C.,
Pastan, I. R.
(1980)
J. Biol. Chem.
255,
1239-1241[Abstract/Free Full Text]
-
Meneton, P.,
Imbert-Teboul, M.,
Bloch-Faure, M.,
and Rajerison, R. M.
(1996)
Am. J. Physiol.
271,
F382-F390[Abstract/Free Full Text]
-
Marchetti, J.,
Meneton, P.,
Lebrun, F.,
Bloch-Faure, M.,
and Rajerison, R. M.
(1995)
Am. J. Physiol.
268,
F1053-F1061[Abstract/Free Full Text]
-
Scatchard, G.
(1949)
Ann. N. Y. Acad. Sci.
51,
660-672[CrossRef]
-
Christoffersen, C. T.,
Bornfeldt, K. E.,
Rotella, C. M.,
Gonzalez, N.,
Vissing, H.,
Shymko, R. M.,
Ten Hoeve, J.,
Groffen, J.,
Heisterkamp, N.,
De Meyts, P.
(1994)
Endocrinology
135,
472-475[Abstract]
-
Heuser, J. E.,
and Anderson, R. G. W.
(1989)
J. Cell Biol.
108,
389-400[Abstract/Free Full Text]
-
Ilondo, M. M.,
Smal, J.,
De Meyts, P.,
Courtoy, P. J.
(1991)
Endocrinology
128,
1597-1602[Abstract/Free Full Text]
-
Nardone, J.,
Gerald, C.,
Rimawi, L.,
Song, L.,
and Hogan, P. G.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
4412-4416[Abstract/Free Full Text]
-
Böckmann, S.,
and Paegelow, I.
(1995)
Eur. J. Pharmacol.
291,
159-165[CrossRef][Medline]
[Order article via Infotrieve]
-
Leeb-Lundberg, L. M.,
Mathis, S. A.,
Herzig, M. C. S.
(1994)
J. Biol. Chem.
269,
25970-25973[Abstract/Free Full Text]
-
Porteu, F.,
and Halbwachs-Mecarelli, L.
(1988)
J. Biol. Chem.
263,
5091-5097[Abstract/Free Full Text]
-
Monnot, C.,
Bihoreau, C.,
Conchon, S.,
Curnow, K. M.,
Corvol, P.,
Clauser, E.
(1996)
J. Biol. Chem.
271,
1507-1513[Abstract/Free Full Text]
-
Wess, J.
(1993)
Trends Pharmacol. Sci.
14,
308-313[CrossRef][Medline]
[Order article via Infotrieve]
-
Wess, J.
(1993)
Life Sci.
53,
1447-1463[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J.-Y. Springael, P. N. Le Minh, E. Urizar, S. Costagliola, G. Vassart, and M. Parmentier
Allosteric Modulation of Binding Properties between Units of Chemokine Receptor Homo- and Hetero-Oligomers
Mol. Pharmacol.,
May 1, 2006;
69(5):
1652 - 1661.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw
International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences
Pharmacol. Rev.,
March 1, 2005;
57(1):
27 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Suzuki, E. Moriyoshi, D. Tsuchiya, and H. Jingami
Negative Cooperativity of Glutamate Binding in the Dimeric Metabotropic Glutamate Receptor Subtype 1
J. Biol. Chem.,
August 20, 2004;
279(34):
35526 - 35534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Faussner, A. Bauer, I. Kalatskaya, M. Jochum, and H. Fritz
Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Expression levels strongly affect ligand-induced sequestration of B2 bradykinin receptors in transfected cells
Am J Physiol Heart Circ Physiol,
June 1, 2003;
284(6):
H1892 - H1898.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Duchene, J. P. Schanstra, C. Pecher, A. Pizard, C. Susini, J.-P. Esteve, J.-L. Bascands, and J.-P. Girolami
A Novel Protein-Protein Interaction between a G Protein-coupled Receptor and the Phosphatase SHP-2 Is Involved in Bradykinin-induced Inhibition of Cell Proliferation
J. Biol. Chem.,
October 18, 2002;
277(43):
40375 - 40383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Christopoulos and T. Kenakin
G Protein-Coupled Receptor Allosterism and Complexing
Pharmacol. Rev.,
June 1, 2002;
54(2):
323 - 374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Marcic and E. G. Erdös
Protein Kinase C and Phosphatase Inhibitors Block the Ability of Angiotensin I-Converting Enzyme Inhibitors to Resensitize the Receptor to Bradykinin without Altering the Primary Effects of Bradykinin
J. Pharmacol. Exp. Ther.,
August 1, 2000;
294(2):
605 - 612.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Dendorfer, S. Wolfrum, U. Schafer, J. M. Stewart, N. Inamura, and P. Dominiak
Potentiation of the Vascular Response to Kinins by Inhibition of Myocardial Kininases
Hypertension,
January 1, 2000;
35(1):
32 - 37.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Praddaude, J. Marchetti, F. Alhenc-Gelas, and J.-L. Ader
Dissimilar mechanisms of Ca2+ response to bradykinin in different types of juxtamedullary glomerular arterioles
Am J Physiol Renal Physiol,
November 1, 1999;
277(5):
F697 - F705.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pizard, A. Blaukat, W. Muller-Esterl, F. Alhenc-Gelas, and R. M. Rajerison
Bradykinin-induced Internalization of the Human B2 Receptor Requires Phosphorylation of Three Serine and Two Threonine Residues at Its Carboxyl Tail
J. Biol. Chem.,
April 30, 1999;
274(18):
12738 - 12747.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Benzing, I. Fleming, A. Blaukat, W. Muller-Esterl, and R. Busse
Angiotensin-Converting Enzyme Inhibitor Ramiprilat Interferes With the Sequestration of the B2 Kinin Receptor Within the Plasma Membrane of Native Endothelial Cells
Circulation,
April 20, 1999;
99(15):
2034 - 2040.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|